Table 4.
Pharmacodynamics (mean ± s.e. [range]) of donepezil at day 1 and at steady state (day 29)
| Day 1 | Day 29 | |||
|---|---|---|---|---|
| Renally impaired (n = 12) | Healthy (n = 11) | Renally impaired (n = 12) | Healthy (n = 10) | |
| AUE0–24 (t·% inhibition) | 475.9 ± 39.8 | 477.1 ± 34.4 | 1563 ± 60.4 | 1455 ± 70.7 |
| (298.5–730.5) | (231.6–648.1) | (1266–1938) | (1076–1715) | |
| Imax (% inhibition) | 32.07 ± 2.00 | 31.69 ± 2.45 | 73.97 ± 1.45* | 66.81 ± 2.63 |
| (23.2–43.1) | (17.3–42.4) | (65.2–82.4) | (49.4–74.5) | |
| tImax (h) | 5.6 ± 0.5 | 4.5 ± 0.5 | 4.1 ± 0.9 | 5.2 ± 1.0 |
| 3–8 | 2–6 | 2–12 | 3–12 | |
| ISS (% inhibition) | – | – | 65.11 ± 2.52 | 60.62 ± 2.95 |
| – | – | (52.7–80.7) | (44.8–71.4) | |
P < 0.03, renally impaired vs. healthy subjects.